Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...
NMPA Approves PARP Inhibitor Pamiparib of BeiGene

NMPA Approves PARP Inhibitor Pamiparib of BeiGene

China’s regulatory body, the National Medical Products Administration (NMPA), has granted conditional approval to BeiGene’s PARP inhibitor pamiparib for treatment of patients advanced ovarian cancer. The approval marks the first for pamiparib and the third...